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Figure S1. High-throughput chemical screening for modulators of naive human pluripotency in 
the presence of 2i [Related to Figure 1]. 
A. Illustration of the multi-parametric data analysis (MPDA) for high-throughput screening in this study. 
Shown is an example dataset from a 5 µM compound screening concentration in presence of MEK, GSK3, 
and ROCK inhibitors (2i/Y) in two biological replicates. Following the extraction of fluorescent object 
shape and intensity statistics, the Mahalanobis distance (MHD) scores were calculated relative to the +DOX 
control wells (active control = AC wells) and hits were called based on those sample wells that showed >1 
SD from the –DOX control wells (negative control = NC wells). Use of the MHD scores allowed 
enumeration of unwanted phenotypes that showed, for example, very bright fluorescence but poor shape 
parameters such as the outlier wells shown that may include compounds showing toxicity leading to very 
bright and round but small objects or those where GFP expression is increased without the desired 
roundness observed in the AC wells. Lines on the graph represent 1 SD of the NC wells. Fluorescent images 
are included of active control (+DOX), negative control (-DOX), and selected hit compounds in presence of 
2i/Y. The scale bar depicts 260 µm.
B. Summary of 33 validated hit compounds from the MoA library screen performed in presence of 2i/Y. 
Compound target annotations showed enrichments in several target classes, some of which have been 
previously been implicated in naive human pluripotency. Novel putative targets were also identified. 
Numbers represent the number of compounds identified that were annotated to the target noted. Hit 
compounds were validated in two biological replicates. A full list of validated hit compounds in presence of 
2i/Y is included in Table S1.
C. Fluorescent images of active control (+DOX), negative control (-DOX), and selected hit compounds in 
presence of 2i/Y. Hit compounds were validated in two biological replicates. The scale bar depicts 260 µm. 
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Figure S2. Efficacy of hit compounds during extended maintenance assays in naive hESCs [Related 
to Figure 2]. 
A. Quantitative gene expression analysis for GFP in WIBR3 OCT4-ΔPE-GFP+ naive hESCs that were 
switched from 5i/L/A to the indicated conditions for two passages. In this experiment hit compounds were 
applied at 5 µM concentration. Error bars indicate mean ± SD of three technical replicates. Data are 
representative of two biological replicates.
B. Phase (Top) and GFP fluorescence (Bottom) images of WIBR3 OCT4-ΔPE-GFP+ naive hESCs derived 
from primed hESCs using 5i/L/A and transferred to serum-free N2B27 medium supplemented only with 
ROCK inhibitor (N2B27/Y) or three alternative culture conditions that maintain GFP activity over two 
passages. Data are representative of two biological replicates. The scale bar depicts 250 µm.
C. Flow cytometry analyses using antibodies against naive-specific cell surface markers CD75 and SUSD2 in 
H9 primed and naive hESCs cultured in mTeSR1 and 5i/L/A media, respectively. Data are representative of 
two biological replicates.
D. Phase contrast (Top), Alkaline phosphatase staining (Middle), and flow cytometry analyses for naïve- 
specific cell surface markers CD75 and SUSD2 (Bottom) in H9 naive hESCs derived in 5i/L/A and 
switched to indicated conditions for two passages. The scale bar depicts 250 µm.
E. Quantitative gene expression analysis for the naive-specific transcription factor KLF17 in H9 naive hESCs 
for the samples shown in (D). Error bars indicate mean ± SD of three technical replicates.
F. Phase (Top) and GFP fluorescence (Bottom) images of WIBR3 OCT4-ΔPE-GFP+ naive hESCs derived 
from primed hESCs using 5i/L/A and maintained for two passages in the absence of the MEK inhibitor 
PD0325901 (5i/L/A-PD03) or upon replacement of PD03 with the RAF inhibitor AZ628. Data are 
representative of two biological replicates. The scale bar depicts 250 µm.
G. Quantitative gene expression analysis for GFP in the samples shown in (F). Error bars indicate mean ± SD 
of three technical replicates. Data are representative of two biological replicates.
H. Phase images (Top), fluorescence images (Middle), and flow cytometry analysis (Bottom) in WIBR3 
OCT4-ΔPE-GFP+ naive hESCs derived from primed hESCs using 5i/L/A and transferred to the indicated 
alternative naive maintenance conditions for two passages. The scale bar depicts 250 µm.
I. Phase images (Top), Alkaline phosphatase (AP) staining (Middle), and flow cytometry analysis using naïve-
specific CD75 and SUSD2 antibodies (Bottom) in wild-type WIBR3 naive hESCs that were derived from 
the primed state in 5i/L/A and maintained in the indicated naive maintenance conditions for two passages. 
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Figure S3. Transcriptome and DNA methylome profiles of alternative naive hPSCs maintained without 
2i [Related to Figure 3]. 
A. Volcano plot showing differentially expressed genes (DEGs) in naive hESCs that were derived in 5i/L/A 
and subsequently maintained in AXGY vs. 5i/L/A. The x-axis plots log2 fold change and the y-axis plots 
significance as -log10(adj. p-value). Significant DEGs in both directions are labeled. Data represent two 
independent genetic backgrounds (H9 and WIBR3).
B. Volcano plot showing differential expression in naive hESCs that were derived in 5i/L/A and subsequently 
maintained in AXGYU vs. 5i/L/A. The x-axis plots log2 fold change and the y-axis plots significance as -
log10(adj. p-value). Significant DEGs in both directions are labeled. Data represent two independent 
genetic backgrounds (H9 and WIBR3).
C. Volcano plot showing differential expression in naive hESCs that were derived in 5i/L/A and subsequently 
maintained in a5i/L/A vs. 5i/L/A. The x-axis plots log2 fold change and the y-axis plots significance as -
log10(adj. p-value). Significant DEGs in both directions are labeled. Data represent two independent 
genetic backgrounds (H9 and WIBR3).
D. Heatmap indicating expression of individual LTR7 integrants in H9 and WIBR3 primed hESCs and naive 
hESCs maintained in 5i/L/A or three alternative naive maintenance conditions.
E. Heatmap indicating expression of individual HERVK integrants in H9 and WIBR3 primed hESCs and 
naive hESCs maintained in 5i/L/A or three alternative naive maintenance conditions.
F. Heatmap indicating expression of individual SVA_D integrants in H9 and WIBR3 primed hESCs and naive 
hESCs maintained in 5i/L/A or three alternative naive maintenance conditions.
G. Tile-based summary of genome-wide DNA methylation levels in H9 primed hESCs and naive hESCs 
maintained in 5i/L/A or three alternative naive maintenance conditions. This barplot shows the fraction of 
1kB tiles with % methylation < 20%, 20 < x < 40 etc. for each condition.
H. Correlation between expression of HERVH integrants (y-axis, log2FC in each alternative condition vs. 5i/
L/A) and DNA methylation (x-axis, % DNA methylation in each alternative condition – 5i/L/A). Red dots 
indicate HERVH integrants that are significantly differentially expressed between the indicated conditions.
I. DNA methylation levels at imprinted DMRs in H9 primed hESCs and naive hESCs that were derived in 5i/
L/A and thereafter switched to three alternative naive maintenance conditions (a5i/L/A, AXGY or 
AXGYU). The coordinates of imprinted DMRs were defined in (Court et al., 2014; Theunissen et al., 2016). 
Target Compound name
ADRB2 ICI 118,551 hydrochloride
BMX BMX-IN-1
CCR1 J113863
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5/20: Trisomy chr 8
7/20: Trisomy chr 3 and 8
3/20: Marker chr
5/20: Normal (20%)
FXGY 20/20: Normal (100%)
PXGY
3/20: Trisomy of chr 8
17/20: Normal (85%)
AXGY 20/20: Normal (100%)
GXGY
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Figure S4. Validation screen with additional compounds and characterization of alternative naive 
maintenance conditions [Related to Figure 4] 
A. List of alternative compounds for selected non-commercially available hit compounds shown in Table S2 and 
their corresponding targets.
B. Flow cytometry analysis with antibodies for naive-specific cell surface markers CD75 and SUSD2 to assess 
the ability of hit compounds to maintain naive hESCs in the presence of TNKS, PKC, and ROCK inhibitors 
(XAV/Gö/Y). 5i/L/A-derived H9 naive hESCs were switched to indicated conditions and maintained for two 
passages.
C. Titration experiment to determine the optimal concentrations of FGFRi (PD166866) and ERKi (GDC-0994) 
to maintain naive hESCs in XAV/Gö/Y. Flow cytometry analysis with antibodies for CD75 and SUSD2 was 
performed in 5i/L/A-derived H9 naive hESCs that were switched to the indicated conditions and maintained 
for two passages.
D. Uniform Manifold Approximation and Projection (UMAP) dimension reduction analysis of scRNA-seq data 
representing the inner cell mass (ICM), pre-implantation epiblast (Pre-EPI), early post-implantation epiblast 
(PostE.EPI), and late post-implantation epiblast (PostL-EPI) from Cynomolgus macaque embryo stages
(Nakamura et al., 2017) compared to the alternative naive maintenance conditions described in Fig. 4C. Gene 
expression was compared to H9 mTeSR1 and 5i/L/A samples previously analyzed in Fig. 3 and an additional 
H9 mTeSR1 sample (mTeSR1_2).
E. DNA methylation levels at imprinted DMRs in H9 primed hESCs and naive hESCs that were derived in 5i/
L/A and thereafter switched to four alternative naive maintenance conditions (FXGY, AXGY, PXGY, and 
GXGY). The coordinates of imprinted DMRs were defined in (Court et al., 2014; Theunissen et al., 2016). 
Data were compared to the H9 mTeSR1 sample previously analyzed in Fig. 3H.
F. Schematic representation of experiments used to assess the capacity of H9 naive hESCs that were maintained 
in the absence of MEK inhibition to undergo re-priming or capacitation into a formative pluripotent state 
using WNT inhibition (Rostovskaya et al., 2019).
G. Flow cytometry histogram indicating gain of the primed-specific cell surface marker CD90 at day 7 of re-
priming of naive hESCs that were maintained in FXGY, AXGY, or GXGY.
H. Quantitative expression analysis for naive (KLF17 and DNMT3L) and formative (ZIC2 and SFRP2) markers 
following 10 days of capacitation. Error bars indicate mean ± SD of three technical replicates.
I. Summary of cytogenetic analyses of H9 naive hESCs maintained under various culture conditions
(table) at P10 with representative images of predominant karyotypes for each culture condition. 
Chromosomal abnormalities in 5i/L/A are highlighted in red circles. For each sample 20 metaphase spreads 
were analyzed.
J. Flow cytometry analysis with antibodies for naive-specific cell surface markers CD75 and SUSD2 in H9 
naive hESCs that were derived in 5i/L/A and switched to alternative maintenance conditions FXGY, AXGY, 
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Figure S5. Examining the signaling requirements during primed-to-naive resetting [Related to Figure 5]. 
A. Experimental scheme to test the alternative naive maintenance conditions a5i/L/A, AXGY, and AXGYU 
during primed-to-naive conversion. Induction of naive pluripotency was assessed by flow cytometry using 
antibodies for the naive-specific cell surface markers CD75 and SUSD2 in H9 cells. Note that a5i/L/A 
consists of 5i/L/A media in which the MEK inhibitor PD03 is replaced with the RAF inhibitor AZ628.
B. Flow cytometry analyses using antibodies for the naive-specific cell surface markers CD75 and SUSD2 in 
H9 hESCs during primed-to-naive conversion in indicated conditions at the end of P1. Data are 
representative of two biological replicates.
C. Flow cytometry analysis using antibodies for the naive-specific cell surface markers CD75 and SUSD2 in 
H9 naive cells that were derived from the primed state in 5i/L/A or PXGGY at P9. Data are representative 
of two biological replicates.
D. Cytogenetic analysis at P14 for primed-to-naive conversion condition PXGGY showing a normal karyotype. 
20 metaphase spreads were analyzed.
E. Flow cytometry analyses of naive WIBR3 MECP2-GFP/tdTomato reporter hESCs that were derived from 
the primed state in 5i/L/A or PXGGY at the end of P1 and P2.
F. DNA methylation levels at imprinted DMRs in naive hESCs that were converted in 5i/L/A or PXGGY/A at 
P5. We also examined naive hESCs that were derived in PXGGY/A and maintained for four additional 
passages in the absence of Activin. Data were compared to the H9 mTeSR1 and 5i/L/A samples previously 
analyzed in Fig. 4I. The coordinates of imprinted DMRs were defined previously (Court et al., 2014; 
Theunissen et al., 2016).
G. Schematic representation of experiments used to assess the capacity of H9 naive hESCs that were derived in 
PXGGY/A and maintained without Activin for two passages to undergo re-priming or differentiation into 
human trophoblast stem cells (hTSCs) (Dong et al., 2020).
H. Phase contrast images (Left) and flow cytometry analyses for hTSC-specific cell surface markers ITGA6 and 
EGFR (Right) of hTSCs derived from H9 naive hESCs that were isolated from the primed state in PXGGY/
A and maintained without Activin for two passages. The scale bar depicts 250 µm.
I. Flow cytometry histogram indicating gain of the primed-specific cell surface marker CD90 during re-
priming of naive hESCs that were derived from the primed state in PXGGY/A and maintained without 
Activin for two passages.
J. Schematic representation of experiments used to assess the capacity of H9 naive hESCs that were derived in 
PXGGY/A to undergo switching to alternative maintenance conditions and their differentiation into human 
trophoblast stem cells (hTSCs) (Dong et al., 2020).
K. Flow cytometry analysis using antibodies for the naive-specific cell surface markers CD75 and SUSD2 in 
H9 naive hESCs that were derived in PXGGY/A and switched to the alternative naive maintenance media 
(FXGY, AXGY, and GXGY) for two passages. These cells were subsequently used for hTSC 
differentiation.
L. Evaluation of the trophoblast potential of H9 naive hESCs that were derived from the primed state in 
PXGGY/A and subsequently maintained in alternative naive media without direct MEK inhibition. Flow 
cytometry analyses for hTSC-specific antibodies ITGA6 and EGFR (Left) and phase contrast images
(Right) of hTSCs derived from indicated naive conditions. H9 cells shown in (K) were used for hTSC 
derivation. The scale bar depicts 250 µm.
M. Phase contrast images (Top), GFP and tdTomato fluorescence images (Middle), and flow cytometry analyses 
(Bottom) of WIBR3 MECP2-GFP/tdTomato reporter hESCs undergoing primed-to-naive conversion using 
various combinations of FGF pathway inhibitors in the presence of XAV/Gö/Y and Activin at the end of P1. 
The scale bar depicts 250 µm. 
